These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

591 related items for PubMed ID: 17893520

  • 1. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV, Forté AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ.
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [Abstract] [Full Text] [Related]

  • 2. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
    Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, Baio G, Neumaier CE, Brignole C, Loi M, Marimpietri D, Pagnan G, Cilli M, Lepekhin EA, Garde SV, Longhi R, Corti A, Allen TM, Wu JJ, Ponzoni M.
    Clin Cancer Res; 2008 Nov 15; 14(22):7320-9. PubMed ID: 19010847
    [Abstract] [Full Text] [Related]

  • 3. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M.
    Cancer Res; 2003 Nov 01; 63(21):7400-9. PubMed ID: 14612539
    [Abstract] [Full Text] [Related]

  • 4. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, Wu W, Shao X, Mao Y, Wei Y, Chen L.
    J Control Release; 2010 Jul 01; 145(1):17-25. PubMed ID: 20307599
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M, Marchiò S, Becherini P, Di Paolo D, Soster M, Curnis F, Brignole C, Pagnan G, Perri P, Caffa I, Longhi R, Nico B, Bussolino F, Gambini C, Ribatti D, Cilli M, Arap W, Pasqualini R, Allen TM, Corti A, Ponzoni M, Pastorino F.
    J Control Release; 2010 Jul 01; 145(1):66-73. PubMed ID: 20346382
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
    Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A.
    Cancer Res; 2002 Feb 01; 62(3):867-74. PubMed ID: 11830545
    [Abstract] [Full Text] [Related]

  • 9. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.
    Clin Cancer Res; 2002 Apr 01; 8(4):1172-81. PubMed ID: 11948130
    [Abstract] [Full Text] [Related]

  • 10. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul 01; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 11. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC, Liu XY, Lü WL, Lee HS, Goh BC, Zhang Q.
    Yao Xue Xue Bao; 2005 May 01; 40(5):475-80. PubMed ID: 16220797
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW.
    Cancer Res; 2000 Dec 15; 60(24):6950-7. PubMed ID: 11156395
    [Abstract] [Full Text] [Related]

  • 13. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
    van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JC, Heijn M, Boven E, Hoekman K, Pinedo HM.
    Biochem Pharmacol; 2002 Mar 01; 63(5):897-908. PubMed ID: 11911842
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V, Dasnois L, Lebtahi K, Collot F, Heylen N, Havaux N, Fernandez AM, Lobl TJ, Oliyai C, Nieder M, Shochat D, Yarranton GT, Trouet A.
    Cancer Res; 2002 Apr 15; 62(8):2327-31. PubMed ID: 11956091
    [Abstract] [Full Text] [Related]

  • 16. PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells.
    Dai W, Yang T, Wang X, Wang J, Zhang X, Zhang Q.
    J Drug Target; 2010 May 15; 18(4):254-63. PubMed ID: 19824864
    [Abstract] [Full Text] [Related]

  • 17. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
    Zhou PH, Yao LQ, Qin XY, Shen XZ, Liu YS, Lu WY, Yao M.
    Zhonghua Yi Xue Za Zhi; 2003 Dec 10; 83(23):2073-6. PubMed ID: 14703420
    [Abstract] [Full Text] [Related]

  • 18. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J, Lee A, Lu Y, Lee RJ.
    Int J Pharm; 2007 Jun 07; 337(1-2):329-35. PubMed ID: 17275230
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
    Shmeeda H, Tzemach D, Mak L, Gabizon A.
    J Control Release; 2009 Jun 05; 136(2):155-60. PubMed ID: 19331844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.